Tag: Sirtex

NHS

SIRT approved for routine commissioning on the NHS

National Health Service (NHS) England have announced that selective internal radiation therapy (SIRT) using yttrium-90 (Y-90) microspheres will now be routinely commissioned for NHS...

Lessons from randomised controlled trials utilising SIRT in liver cancer

A recent session at CIRSE 2018 sought to go beyond the headline findings from a number of recent randomised controlled trials (RCTs) in interventional...

Sirtex prefers US$1.4 billion CDH-CGP bid to Varian’s acquisition offer

Sirtex has announced entering into a binding scheme implementation deed with CDH Genetech (CDH) and China Grand Pharmaceuticals and Healthcare Holdings Limited (CGP). It...

Establishing the evidence base for SIRT in Interventional Oncology

Multidisciplinary oncology thought leaders discuss the personalisation of SIRT, new and recent evidence for the minimally invasive procedure over sorafenib in advanced HCC, the...

SIRT fails to extend survival in the SORAMIC study palliative cohort

  The SORAMIC study, presented at The International Liver Congress, shows that the addition of selective internal radiation therapy (SIRT) to sorafenib in patients with...

Varian signs agreement to acquire Sirtex

Varian Medical has announced it has signed an agreement to acquire all the outstanding shares of Sirtex Medical for A$28 per share in cash....

REsect study shows SIRT makes metastatic colorectal cancer patients more likely...

Metastatic colorectal cancer patients treated first-line with SIR-spheres Y-90 resin microspheres more likely to become candidates for potentially curative liver surgery, the REsect study...

SIRT significantly better tolerated than sorafenib, but does not increase overall...

The 459-patient randomised controlled SARAH study shows that local treatments of advanced or inoperable hepatocellular carcinoma with selective internal radiation therapy (SIRT) did not...

New NCCN guidelines recommend SIRT for the treatment of metastatic colorectal...

Sirtex has announced that SIR-Spheres Y-90 resin microspheres have been included as a Category 2A recommended treatment in the latest National Comprehensive Cancer Network...

New ESMO biliary cancer guidelines indicate radioembolization as an option for...

New European Society of Medical Oncology (ESMO) biliary cancer guidelines indicate yttrium-90 (Y-90) therapy as an option for post-chemotherapy treatment of intrahepatic cholangiocarcinoma. Sirtex has announced...